Quantcast

Latest PharmAthene Inc. Stories

2014-06-09 12:23:15

ANNAPOLIS, Md., June 9, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that the U.S. Patent and Trademark Office issued U.S. patent number 8,729,245 to PharmAthene, with claims that cover methods for the production of its recombinant butyrlcholinesterase (rBChE) bioscavenger in mammalian cells. PharmAthene is initially developing rBChE as a pre- and post-exposure therapy for military and civilian victims of nerve agent attacks. "Organophosphorus compounds, including...

2014-06-04 12:29:22

ANNAPOLIS, Md., June 4, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that new data from its SparVax(®) anthrax vaccine program were recently presented at the 2014 U.S. Food and Drug Administration (FDA) Medical Countermeasures Initiative (MCMi) Regulatory Science Symposium in Silver Spring, MD. In a presentation entitled, "Recombinant Protective Antigen Vaccine (SparVax(®)) Provides Protection Equivalent to BioThrax(®) Against Lethal Challenge with Bacillus...

2014-05-29 12:28:35

ANNAPOLIS, Md., May 29, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that new analytical data from the Company's SparVax(®) anthrax vaccine program were presented at the 114(th) General Meeting of the American Society for Microbiology (ASM), held recently in Boston, Massachusetts. In a poster presentation entitled "Evidence Correlating Changes in Structure and Biological Activity for a Recombinant Protective Antigen (rPA) Anthrax Vaccine," Dr. Bradford Powell,...

2014-05-08 16:21:24

ANNAPOLIS, Md., May 8, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological( )and chemical threats, today reported its financial and operational results for the first quarter of 2014. For the three months ended March 31, 2014, PharmAthene recognized revenue of approximately $3.7 million, compared to approximately $6.5 million for the corresponding period in 2013. Revenue was derived primarily from contracts with...

2014-04-07 08:32:23

ANNAPOLIS, Md., April 7, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that it has received notice from the Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA), advising the Company of its decision to de-scope the current SparVax(®) anthrax vaccine contract through a partial termination for convenience. BARDA will provide additional guidance to PharmAthene on the contractual changes, following which...

2014-04-01 16:25:27

ANNAPOLIS, Md., April 1, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) announced today that data from the Company's SparVax(® )next-generation anthrax vaccine program were recently presented at the 8(th) Annual New Technologies, New Vaccines conference. In a presentation entitled, "Factors that Affect Potency and Stability for a Recombinant Protective Antigen Vaccine," Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented results demonstrating the Company's...

2014-03-11 16:20:56

ANNAPOLIS, Md., March 11, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological( )and chemical threats, today reported its financial and operational results for the year ended December 31, 2013. "We remain focused on advancing our core biodefense programs, including addressing the SparVax(®) clinical hold which is our top priority," said Eric I. Richman, President and Chief Executive Officer. "We have a clear path...

2014-03-10 12:21:12

ANNAPOLIS, Md., March 10, 2014 /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP) a biodefense company developing medical countermeasures against biological and chemical threats, announced today that its financial and operational results for the year ended 2013 will be released on Tuesday, March 11, 2014. PharmAthene management will be hosting a conference call to discuss the Company's year-end 2013 financial and operational results. The call is scheduled to begin at 4:30 p.m....


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related